<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90725">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01918553</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX2012/31</org_study_id>
    <nct_id>NCT01918553</nct_id>
  </id_info>
  <brief_title>Cohort Study on the Age-related Macular Degeneration: Incidence and Research for Predisposing Factors</brief_title>
  <acronym>ECLAIR</acronym>
  <official_title>Cohort Study on the Age-related Macular Degeneration: Incidence and Research for Predisposing Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Age-related Macular Degeneration (AMD) is the most cause of blindness in the industrialised
      countries. There are few epidemiological studies on the incidence of this disease. Studying
      the incidence of AMD in an elderly French population and identifying the predisposing
      factors is very important to allow a major advance in the epidemiological knowledge of AMD.
      This study will contribute to the identification of the clinical, genetic and modifiable
      parameters associated at the risk of developing AMD. This could result in means prevention
      as well as in the identification of subjects as high risk of AMD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Age-related Macular Degeneration is the most cause of blindness in the industrialised
      countries. There are few French epidemiological data on this disease. Worldwide, studies
      have included a small number of very old subjects. Thus, it is important to estimate the AMD
      incidence in an elderly French population, in order to evaluate more precisely the number of
      cases in the French population. Besides, some clinical, genetic and modifiable parameters
      predisposing to the AMD are under study. The aim of the ECLAIR project is to study the
      8-year incidence of AMD in an elderly French population and to identify the predisposing
      factors. It is based on an existing cohort study (ALIENOR) in which some clinical, genetic
      and modifiable data were collected at baseline, 2 and 4 years. It is the only cohort study
      performed in France in this field since fifteen years in parallel with another one performed
      in Dijon according to the same methodology. It is important to extend the study to 8 years
      in order to have a sufficient statistical power for the identification of predisposing
      factors. In the ECLAIR study, there is no treatment. The subjects will be followed during 2
      years (6 and 8 years after baseline of the Alienor study). The visit 1 (A0) will be the
      inclusion visit where the subjects will sign the inform consent and will perform
      ophthalmological examinations. The subjects will come back 2 years later for the visit 2
      (A2). In this second visit, the ophthalmological examinations will be the same that is:
      measure of clinical parameters, measurement of visual acuity exams,
      retinophotography,spectral domain optical coherence tomography (SD-OCT), intraocular
      pressure, retinal imaging (OPTOMAP), axial length (IOL master)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>8-year incidence of late AMD (neovascular and/or atrophic)</measure>
    <time_frame>at day 0 (inclusion in ECLAIR study and 6 years after inclusion in ALIENOR cohort) and year 2 after inclusion (end of ECLAIR study and 8 years after inclusion in ALIENOR cohort)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>best-corrected visual acuity (ETDRS methodology) measured in visit 1 and 2 years later with ETDRS methodology</measure>
    <time_frame>at day 0 (inclusion) and year 2 after inclusion (end of study)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Elderly French Population</condition>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Subject in the study ALIENOR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical parameters</intervention_name>
    <arm_group_label>Subject in the study ALIENOR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>visual acuity exams</intervention_name>
    <arm_group_label>Subject in the study ALIENOR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>retinophotography</intervention_name>
    <arm_group_label>Subject in the study ALIENOR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SD-OCT</intervention_name>
    <arm_group_label>Subject in the study ALIENOR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intra ocular Pressure (IOP)</intervention_name>
    <arm_group_label>Subject in the study ALIENOR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>retinal imaging (OPTOMAP)</intervention_name>
    <arm_group_label>Subject in the study ALIENOR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>axial length (IOL master)</intervention_name>
    <arm_group_label>Subject in the study ALIENOR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject participating in the study ALIENOR

          -  Affiliated to a social security

          -  Consent signed by the patient and the investigator

        Exclusion Criteria:

        - Health incompatible with one hour and a half ophthalmic examination
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Korobelnik Jean-François</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Korobelnik Jean-François</last_name>
    <phone>+33 (0) 556 795 741</phone>
    <email>jean-francois.korobelnik@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ROUGIER Marie Bénédicte</last_name>
    <phone>+33 (0) 556 795 741</phone>
    <email>marie-benedicte.rougier@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unité Médicale Rétine Neuro-Ophtalmologie - Service d'Ophtalmologie - Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Korobelnik Jean-François</last_name>
      <phone>+33 (0) 556 795 741</phone>
      <email>jean-francois.korobelnik@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>ROUGIER Marie Bénédicte</last_name>
      <phone>+33 (0) 556 795 741</phone>
      <email>marie-benedicte.rougier@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>DELYFER Marie Noelle</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ROUGIER Marie Bénédicte</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Korobelnik Jean-François</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>July 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>epidemiology</keyword>
  <keyword>risk factors</keyword>
  <keyword>cohort study</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
